On May 5, 2026, Exelixis management reiterated full-year 2026 financial guidance. Weeks later, the C

Arkadios Wealth Advisors bought a new position in Exelixis, Inc. (NASDAQ: EXEL) during the undefined

Amundi cut its position in Exelixis, Inc. (NASDAQ: EXEL) by 77.9% during the first quarter, accordin

Exelixis beats EPS estimates but misses on revenues; cuts 2026 outlook as a slower-than-expected NET

Exelixis NASDAQ: EXEL reported second-quarter 2026 revenue of approximately $629 million, including

While the top- and bottom-line numbers for Exelixis (EXEL) give a sense of how the business performe

Exelixis, Inc. (EXEL) Q2 2026 Earnings Call Transcript

Exelixis (EXEL) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Est

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i

Krystal Biotech is posting strong sales thanks to a breakthrough in an underserved therapeutic area.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both

Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raise

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quar

Bank of New York Mellon Corp lowered its holdings in shares of Exelixis, Inc. (NASDAQ: EXEL) by 2.8%

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings bea

Allspring Global Investments Holdings LLC grew its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 23.4

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combin

Barclays analyst Etzer Darout maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the

Wells Fargo analyst Eva Fortea Verdejo maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and r

These three biotechs are posting strong revenue growth. Brand-new launches and label expansions shou

Exelixis' zanzalintinib faces a setback, but an FDA review, phase III trials and Cabometyx momentum

Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratin

Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidanc

Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record

Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.

Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1

Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is estimated to report earnings for it

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn

Upgrades

Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.

  On Tuesday, 838 companies hit new 52-week lows.

  During Monday's trading, 528 companies set new 52-week lows.

  On Friday, 404 stocks made new 52-week lows.

  On Thursday, 142 companies hit new 52-week lows.

  Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to repor

  Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly

  Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report q